Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection

Jean-Michel Molina presents the results of PHOTON-2. Photo by Liz Highleyman,
Published: 21 July 2014

An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained hepatitis C virological response in 84 to 89% of HIV-positive people with chronic hepatitis C genotypes 1, 2, 3 or 4, according to results from the phase 3 PHOTON-2 study presented on Monday at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia. Cure rates were lower, however, for genotype 1a patients with liver cirrhosis.

People with HIV and hepatitis C virus (HCV) co-infection experience more rapid liver disease progression than people with hepatitis C alone and do not respond as well to interferon-based therapy. Direct-acting antivirals that target different steps of the HCV lifecycle offer the prospect of shorter treatment, fewer side-effects and higher cure rates for people with HIV and HCV co-infection as well as for people with HCV mono-infection.

Jean-Michel Molina from University of Paris Diderot presented data from the phase 3 PHOTON-2 trial, which included 274 people with co-infection in Europe and Australia. Most participants (81%) were men and the mean age was 47 years. The most common HCV genotypes were 1 (41%) and 3 (39%), followed by 4 (11%) and 2 (9%). Most people with genotype 1 had harder-to-treat subtype 1a.

Most participants (80%) had not been treated previously for hepatitis C. Overall, 20% had cirrhosis (13% of previously untreated, rising to 45% of treatment-experienced). Nearly half had the favourable IL28B CC gene variant.

Almost all study participants were on stable suppressive antiretroviral therapy for HIV and the mean CD4 cell count was nearly 600 cells/mm3. The most commonly used antiretrovirals were efavirenz (Sustiva, also in the Atripla co-formulation) at 25%, raltegravir (Isentress) at 23%, ritonavir-boosted darunavir (Prezista) at 21% and boosted atazanavir (Reyataz) at 17%. All used an NRTI combination of tenofovir and emtricitabine (the drugs in Truvada). Early studies found no clinically relevant drug-drug interactions between sofosbuvir and these antiretrovirals, and sofosbuvir is already approved in Europe and the U.S. for coinfected patients.

All participants received Gilead Sciences' HCV polymerase inhibitor sofosbuvir (400mg once daily) plus ribavirin (weight-based 1000-1200 mg/day). A small number of previously untreated participants with HCV genotype 2 (19 people) were treated for 12 weeks, while all treatment-experienced people and everyone with harder-to-treat genotype 1 or 4 were treated for 24 weeks.

Sustained virological response rates at 12 weeks after completing treatment (SVR12) were 85% for people with genotype 1, 88% for those with genotype 2, 89% for genotype 3 and 84% for genotype 4. Relapse rates were 13%, 8%, 9% and 16%, respectively. One person with genotype 3 experienced viral breakthrough during treatment.

Among the participants with HCV genotype 1, response rates were higher for people who did not have liver cirrhosis (88% overall, 87% for subtype 1a and 100% for subtype 1b) compared to those with cirrhosis (65%, 62% and 75%, respectively). Presence of cirrhosis was the only significant risk factor for poorer response in a multivariate analysis.

For people with other genotypes, cirrhosis had less impact, although the effect was a bit larger for treatment-experienced compared to treatment-naive participants with genotypes 2 or 3.

Response rates did not differ significantly between HCV subtypes 1a and 1b, but the number with the latter type was small. Likewise, there were too few people not taking antiretroviral therapy to permit a separate analysis.

Looking at HIV-related outcomes, four people experienced intermittent low-level HIV viral load breakthrough, though none required modification of their antiretroviral regimen. Absolute CD4 cell counts increased temporarily during hepatitis C treatment, but CD4 percentages remained stable.

Sofosbuvir plus ribavirin was generally safe and well-tolerated. Six people experienced serious adverse events and three stopped treatment early due to adverse events.

The most frequent side-effects among people treated for 24 weeks were fatigue (20%), insomnia (17%), headache (16%), nausea (15%) and diarrhoea (11%). One in five developed grade 3-4 laboratory abnormalities, most commonly elevated bilirubin among people taking atazanavir. While 10% developed low haemoglobin levels – a known side-effect of ribavirin – only one person had severe anaemia.

"Sofosbuvir + ribavirin resulted in high SVR12 rates in HIV patients coinfected with HCV genotype 1, 2, 3 or 4," the PHOTON-2 researchers concluded. "Sofosbuvir was well tolerated, with a low rate of treatment discontinuations due to adverse events."

"[this combination] might be attractive in places where you don't have access to all the new drugs." Jean-Michel Molina

Results from the PHOTON-1 study were published this week in the Journal of the American Medical Association. This study tested the same regimens in people with HIV and HCV co-infection, but it was conducted in the US and had a different genotype distribution that allowed for other subgroups comparisons. Just over half had HCV genotype 1 (79% with 1a), while the remainder were roughly evenly split between genotype 2 and 3.

As previously reported at this year's Conference on Retroviruses and Opportunistic Infections (CROI), the overall SVR12 rate for people with genotype 1 was 76%. Among those with genotype 2, response rates were similar for treatment-naive people treated for 12 weeks and treatment-experienced people treated for 24 weeks (88% and 92%, respectively). Among those with genotype 3, however, previously untreated patients taking the shorter duration had a lower response rate (67% vs 94%).

The response rates in the PHOTON trials are not particularly impressive compared to the 90-100% SVR12 rates seen in several other recent interferon-free studies. Sofosbuvir works better when combined with other direct-acting antivirals such as the NS5A inhibitors ledipasvir or daclatasvir (Daklinza), which are expected to be approved soon. A disadvantage of ledipasvir is that it does not have potent activity against HCV genotypes 2 or 3.

Molina suggested that sofosbuvir plus ribavirin may be a good option for people who have HIV and HCV co-infection, with genotype 2 or 3 HCV, who do not have liver cirrhosis. "Ribavirin is generic," he noted, and this combination "might be attractive in places where you don't have access to all the new drugs."

At a separate session discussing the hepatitis C treatment revolution and how to make recent advances available worldwide, Andrew Hill of Liverpool University and others noted that pangenotypic drugs – those that work against multiple HCV genotypes – could potentially mean we will not need genotype testing, which would lower the overall cost of care.


Molina JM et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients co-infected with HIV (PHOTON-2). 20th International AIDS Conference, abstract MOAB0105LB, Melbourne, 2014.

View the abstract on the conference website.

Sulkowski M et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312:353-361, 2014.

Hepatitis information

For more information on hepatitis visit

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit >

NAM’s AIDS 2014 bulletins have been made possible thanks to support from Bristol-Myers Squibb. NAM's wider conference news reporting services have been supported by AbbVie, Gilead Sciences, Janssen and ViiV Healthcare’s Positive Action Programme.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.